The ratio between effector CD8+IFNγ+ and CD4+IL-4+ T cells, the latter commonly endowed with a pro-tumor ability (29), was tipped in favour of effector cells in the SULT2B1b-4T1 TME. The gene discussed is IL4; the disease is neoplasm.